利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.035 秒)

    Urea-containing peptides as inhibitors of viral replication
    11.
    发明授权
    Urea-containing peptides as inhibitors of viral replication 失效
    含尿素肽作为病毒复制的抑制剂

    公开(公告)号：US08163693B2

    公开(公告)日：2012-04-24

    申请号：US12236855

    申请日：2008-09-24

    申请人： Dawei Chen ,  Milind Deshpande ,  Avinash Phadke

    发明人： Dawei Chen ,  Milind Deshpande ,  Avinash Phadke

    IPC分类号： A61K38/00

    CPC分类号： C07K5/0823 ,  A61K38/00 ,  C07K5/06165

    摘要： The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R1-R9, J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

    摘要翻译： 本发明提供式I化合物的含脲的肽化合物及其药用盐和水合物。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在本文中定义。 某些式I化合物可用作抗病毒剂。 本文公开的某些含脲的肽化合物是病毒复制的有效和/或选择性抑制剂，特别是丙型肝炎病毒复制。 本发明还提供含有一种或多种含尿素的肽化合物和一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 这样的药物组合物可以含有含有肽化合物作为唯一活性剂的尿素，或者可以含有含尿素的肽化合物和一种或多种其它药学活性剂的组合。 本发明还提供了用于治疗哺乳动物中的病毒感染（包括丙型肝炎感染）的方法。

    THIAZOLE COMPOUNDS AND METHODS OF USE
    17.
    发明申请
    THIAZOLE COMPOUNDS AND METHODS OF USE 审中-公开
    噻唑化合物及其使用方法

    公开(公告)号：US20120108576A1

    公开(公告)日：2012-05-03

    申请号：US13307761

    申请日：2011-11-30

    申请人： Suoming Zhang ,  Avinash Phadke ,  Cuixian Liu ,  Xiangzhu Wang ,  Jesse Quinn ,  Dawei Chen ,  Venkat Gadhachanda ,  Shouming Li ,  Milind Deshpande

    发明人： Suoming Zhang ,  Avinash Phadke ,  Cuixian Liu ,  Xiangzhu Wang ,  Jesse Quinn ,  Dawei Chen ,  Venkat Gadhachanda ,  Shouming Li ,  Milind Deshpande

    IPC分类号： A61K31/541 ,  A61K31/5377 ,  A61K31/498 ,  A61K31/501 ,  A61K31/496 ,  A61K31/497 ,  A61K31/519 ,  A61K31/506 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/433 ,  A61K31/429 ,  A61K31/426 ,  A61K31/427 ,  C07D239/02 ,  C07D513/14 ,  C07D471/04 ,  C07D417/04 ,  C07D513/04 ,  C07D417/14 ,  C07D277/38 ,  A61K31/538

    CPC分类号： C07D487/04 ,  C07D277/38 ,  C07D277/42 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04

    摘要： The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar1, R2, R3, R4, r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.

    摘要翻译： 本发明提供式I的化合物，盐和水合物，其中变量Ar1，R2，R3，R4，r，q和t在本文中定义。 某些本文所述的式I化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式I化合物。 本文所述的某些化合物抑制HCV复制复合物的组装。 本发明还提供含有一种或多种式I化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效降低疾病体征或症状的式I化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括给予式I化合物作为单一活性剂或将一种式I化合物与一种或多种其它治疗剂组合施用。

    Azabenzofuran substituted thioureas; inhibitors of viral replication
    20.
    发明授权
    Azabenzofuran substituted thioureas; inhibitors of viral replication 失效
    氮杂苯并呋喃取代的硫脲; 病毒复制抑制剂

    公开(公告)号：US07439374B2

    公开(公告)日：2008-10-21

    申请号：US11029910

    申请日：2005-01-05

    申请人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    发明人： Andrew Thurkauf ,  Dawei Chen ,  Avinash Phadke ,  Shouming Li ,  Milind Deshpande

    IPC分类号： C07D401/02 ,  A61K31/44

    CPC分类号： A61K31/00 ,  A61K31/4355 ,  C07D491/04

    摘要： The present invention provides compounds of Formula 1, wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W, X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

    摘要翻译： 本发明提供式1的化合物，其中变量Ar，A 1，A 2，A 3，A 4， R 5，R 6，R 7，V，W，X和Y在本文中定义。 某些本文所述的式1的化合物具有有效的抗病毒活性。 本发明还提供了作为丙型肝炎病毒复制的有效和/或选择性抑制剂的式1化合物。 本发明还提供含有一种或多种式1化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。 本发明还包括通过向这些患者施用一定量的有效减少疾病体征或症状的式1化合物来治疗患有某些感染性疾病的患者的方法。 这些传染病包括病毒感染，特别是HCV感染。 本发明特别包括治疗患有感染性疾病的人类患者的方法，还包括治疗其它动物（包括患有传染病的家畜和驯养的伴侣动物）的方法。 治疗方法包括施用作为单一活性剂的式1化合物或与一种或多种其它治疗剂组合施用式1的化合物。